ABI-MS

status: PUBLIC

text: Cohort of 147 patients (103 female, 44 male) diagnosed with MS

characteristic: description

text: multiple sclerosis

characteristic: disease state

characteristic: number of patients

text: Homo sapiens

characteristic: organism

text: RNA

characteristic: organism part

text: DNA

text: plasma

text: PBMCs

text: ABIRISK

characteristic: project

text: Patients with MS or Clinically Isolated Syndrome (CIS) diagnosis according to McDonald criteria and who were prescribed IFN-beta-1a intramuscularly (IM), IFN-beta-1a subcutaneously (SC), or IFN-beta-1b SC (original product or biosimilar) were recruited from January 30, 2014 to January 22, 2016. Patients who were not naive to IFN-beta were excluded.

characteristic: study description


ABI-RA

text: Cohort of 229 patients (176 female, 53 male) diagnosed with RA

text: juvenile idiopathic arthritis

text: rheumatoid arthritis

text: Homo sapiens

text: RNA

text: DNA

text: plasma

text: PBMCs

text: ABIRISK

text: Patients with RA diagnosis according to 2010 ACR/EULAR criteria and who were prescribed for the first time a BP among the TNF inhibitors adalimumab, infliximab (original product or biosimilar), etanercept, the anti-CD20 antibody rituximab, or the anti-IL6R antibody tocilizumab (administered SC or intravenously) as first-line or second-line therapy were recruited from March 3, 2014 to June 21, 2016. Patients who were not naive for the biotherapy they were given in the study were excluded.


ABI-IBD

text: Cohort of 184 patients (89 female, 95 male) diagnosed with IBD

text: Crohn's disease

text: ulcerative colitis

text: inflammatory bowel disease

text: Homo sapiens

text: RNA

text: DNA

text: plasma

text: PBMCs

text: ABIRISK

text: Patients with Crohn’s disease or ulcerative colitis diagnosis according to ECCO guidelines and who were prescribed adalimumab or infliximab (original product or biosimilar) were recruited from September 11, 2013 to February 15, 2016. Patients who were not naive to TNF inhibitor therapy or who were treated with corticoids more than 30 mg/day over the last 15 days were excluded.


APPROACH source cohorts

text: Collection of 5 existing European OA cohorts used to identify subjects for a new longitudinal cohort via machine learning models trained on historical data to estimate the progression probability for each subject. Novel cohort will also include age-matched healthy controls as well as end-stage established OA patients assigned to 'dominant' progressive subclasses of clinically defined knee osteoarthritis with potential involvement of hip and/or hand OA with each a paired non-progressive knee OA phenotype

text: knee osteoarthritis

text: osteoarthritis

text: Homo sapiens

text: APPROACH

text: historical clinical data

characteristic: sample type

text: imaging data

text: biomarkers

text: All baseline cohort parameters, clinical, conventional (knee x-ray and MRI and the robust biochemical markers), and novel markers (T2 relaxation MRI for cartilage collagen distribution, gagCEST MRI cartilage for proteoglycan content, knee CT/x-ray for bone shape and trabecular architecture, knee motion, and novel biochemical markers describing turnover of specific tissue component, as well as involvement of hand, hip and spine joint damage, hand joint inflammation, hip motion and shape and bone architecture) will be used to identify (a set of) predictors that can discriminate between the knee OA progressors and (paired) non-progressors within a specific phenotype.


name: APPROACH prospective longitudinal cohort

text: 44-82 years

characteristic: age

text: 18.3-47.5 kg/m2

characteristic: bmi

text: Cohort of 297 patients (230 female, 67 male) diagnosed with OA and selected for the expected progression of their condition

text: knee osteoarthritis

text: osteoarthritis

text: 1.39-2.04 meters

characteristic: height

text: Homo sapiens

text: urine

text: serum

text: blood

text: APPROACH

text: questionnaire

text: imaging data

text: biomarkers

text: tissue sample

text: clinical data

text: APPROACH prospective longitudinal study of knee osteoarthritis progression to support drug development

text: 47-140 kg

characteristic: weight